

Real-world Utilization And Amyloid Positivity Patterns Of ¹¹C-PiB PET Across Cognitive Syndromes In A Latin American Memory Center.

Bustos Zamora, JI¹; Chrem Mendez, P¹; Sarandria, ME¹; Surace, E²; Bérnago, Y³; Allegri, RF¹; Vazquez, S³

Affiliations: 1 Centro de Memoria, Fleni, Ciudad Autónoma de Buenos Aires, Argentina. 2 Laboratorio de enfermedades neurodegenerativas (LEN), Fleni, Ciudad Autónoma de Buenos Aires, Argentina. 3 Centro de imágenes moleculares (CIM), Fleni, Ciudad Autónoma de Buenos Aires, Argentina.


TAKE HOME MESSAGES

- Largest real-world amyloid PET cohort reported from Latin America (n = 1,451).
- Amyloid PET positivity closely matched the expected biological probability across clinical syndromes.
- Highest amyloid positivity (>85%) was observed in typical and atypical Alzheimer's disease phenotypes.
- Real-world findings mirrored international data, supporting the implementation of biomarker-based diagnosis in Latin America.

INTRODUCTION

Amyloid PET is a key biomarker for the in vivo detection of Alzheimer's disease pathology, but real-world evidence from Latin America remains limited. We aimed to characterize the clinical use of amyloid PET and amyloid positivity patterns across cognitive syndromes in a tertiary memory center in Argentina.

METHODS



1451 ¹¹C-Pittsburgh compound B (PiB) PET

Performed between 2013 and 2023

Referral source, demographics, pre-test diagnoses, and amyloid positivity rates across clinical syndromes were evaluated according to pre-test probability of AD pathology.

RESULTS

A total of **1451** PiB-PET scans were performed, representing the largest amyloid PET cohort reported from Latin America.

Posterior cortical atrophy

Early onset AD dementia

Late onset AD dementia

Logopenic variant PPA

**HIGH
CONCORDANCE
POSITIVITY
>85%**

Amnesic multidomain MCI

Pure amnesic MCI

Non-amnesic multidomain MCI

Non-amnesic single-domain

**INTERMEDIATE
CONCORDANCE
POSITIVITY**

Primary affective disorders

Cognitively normal

Behavioral variant FTD

**LOW
CONCORDANCE
POSITIVITY
<40%**


0 20 40 60 80 100

PET-driven diagnostic changes followed biologically plausible AD trajectories.

High pre-test probability patients were:



Older
72.4 vs 69.3 years (p = 0.0001)



Evaluated earlier

4.5 vs 6.1 years from symptom onset
(p = 0.0044)

CONCLUSION

This study provides the **largest real-world evidence from Latin America** on amyloid PET utilization. The observed positivity patterns support the clinical validity of amyloid PET and its growing role in biomarker-guided diagnosis in the era of disease-modifying therapies.